Valentis Inc said it expanded its April 2001 license agreement with GlaxoSmithKline PLC to enable GlaxoSmithKline to use its GeneSwitch gene regulation technology for research purposes for up to 10 years.
Valentis will receive €1.1m under the expanded agreement.
CONNECT WITH US TODAY
Be the first to know the latest news and updates
Newsletter
News and analysis on business, money and jobs from Munster and beyond by our expert team of business writers.
Push Notifications
By clicking on sign up you will be the first to know about a selection of business content on this browser. Please note if you are unable to sign up via your mobile web browser, download and sign up for mobile push notifications via our FREE news app.
Sign UpNewsletter
News and analysis on business, money and jobs from Munster and beyond by our expert team of business writers.
Newsletter
Keep up with stories of the day with our lunchtime news wrap and important breaking news alerts.
Thursday, December 11, 2025 - 9:00 PM
Thursday, December 11, 2025 - 9:00 PM
Thursday, December 11, 2025 - 1:00 PM
